This new article from MDB Communications reviews some of the highlights from the 32nd Annual J.P. Morgan Healthcare Conference (JPMHC). The 7-page report is available electronically as a PDF file. To view the report, please click here.
Last week, thousands of registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference [JPMHC] to hear 25-minute presentations from 364 life science companies. For industry executives and investors, deal activity emanating from the annual event typically se
“It’s déjà vu all over again” – Yogi Berra With Opening Day less than a month away, it seems only fitting to reference one of the most quoted personalities of our time to describe our analysis of the biotechnology sector in 2010. In this article, we review our favorable outlook
At the start of the year I provided a positive outlook for the biotechnology industry in 2009, citing the sector’s defensive characteristics, favorable technical aspects, and improving fundamentals, such as the number of new product approvals, products in clinical trials and the brisk
After a brief bout of euphoria during the early portion of the decade, the biotechnology industry, as measured by the Amex Biotech Index (BTK), was shunned by investors for the better part of the 1990’s. The BTK, which was established with a benchmark value of 200 on October 18, 1991,